The challenge of bladder cancer diagnosis and monitoring
Bladder cancer is associated with high recurrence rates, requiring frequent follow-up through invasive procedures such as cystoscopy.
Repetitive invasive procedures
Impact on patients’ quality of life
High healthcare costs
Need for complementary diagnostic tools
This scenario represents a significant burden for both patients and healthcare systems, highlighting the need for more precise and less invasive complementary diagnostic tools.
A solution based on scientific evidence
BlaDimiR is a diagnostic system based on the detection of miRNA biomarkers in urine samples using RT-qPCR technology. It has been developed to improve diagnostic precision and support clinical follow-up in a non-invasive way.
Molecular analysis from urine samples
Clinically validated RT-qPCR technology
Reproducible and reliable results
The challenge of bladder cancer diagnosis and monitoring
Bladder cancer is associated with high recurrence rates, requiring frequent follow-up through invasive procedures such as cystoscopy.
This scenario represents a significant burden for both patients and healthcare systems. It also highlights the need for more precise and less invasive complementary diagnostic tools.
Invasive and repetitive procedures
Impact on patients’ quality of life
High healthcare costs
Need for complementary diagnostic tools
A solution based on scientific evidence
Danae Urogenomics has developed a diagnostic approach based on urinary miRNA biomarkers, designed to improve clinical precision in a non-invasive way.
Advanced molecular analysis
Non-invasive diagnosis
Reliable and reproducible results
Detection of miRNA biomarkers using RT-qPCR technology, with clinically validated sensitivity and specificity.
A complementary alternative to cystoscopy, based on a simple urine sample, designed to improve the patient experience and support clinical follow-up.
A solution designed for integration into clinical and laboratory environments with high analytical robustness.
From urine sample to clinical result
Danae Urogenomics has developed a diagnostic approach based on urinary miRNA biomarkers, clinically validated and designed to improve diagnostic precision in a non-invasive way.
Non-invasive urine sample
Collection of a non-invasive urine sample, easily integrated into routine clinical practice.
Extraction and quantification of miRNA biomarkers using highly sensitive RT-qPCR technology.
Analysis of results through proprietary algorithms that ensure consistency and diagnostic precision.
High-precision molecular analysis
Advanced data interpretation
Advanced molecular analysis
Generation of a clear and actionable report to support patient diagnosis and follow-up.
Scientific evidence and clinical validation
BlaDimiR has been developed on a solid scientific foundation, supported by clinical validation, international scientific publications and intellectual property protection.
Scientific publications
Results published in high-impact scientific journals supporting the robustness and reproducibility of the BlaDimiR system in clinical settings.
Technology protected through international patents in Europe and the United States, with positive assessment regarding novelty and inventive step.
Patent protection
Validation
Ongoing clinical validation with reference institutions, designed to support integration into routine medical practice.
High diagnostic precision
Sensitivity above 90%.
High specificity in the detection and monitoring of bladder cancer using urinary miRNA biomarkers.
✔ Clinically validated RT-qPCR-based technology
✔ miRNA biomarkers with high sensitivity and specificity
✔ Development supported by translational research in uro-oncology
Request Clinical Information
Our scientific team will contact you to provide further information about the clinical application of BlaDimiR for the diagnosis and monitoring of bladder cancer.
info@durogenomics.com
